Movers to Watch: 3M Co (NYSE:MMM), Biogen Inc (NASDAQ:BIIB)

On Tuesday, Shares of 3M Co (NYSE:MMM), added 0.77% and closed at $174.24 in the last trading session. The last trading range of the stock ranges between $171.91 and $174.25. The company’s Market capitalization is $103.50 Billion with the total Outstanding Shares of 601.47 million. During the 52-week trading session the minimum price at which share price traded, registered at $134.64 and reached to max level of $182.27. The EPS of company is strolling at 7.94. 3M Food Safety, a worldwide leader in innovative solutions that assist the food and beverage industries ensure safety and quality in their products, is proud to offer safety from the start with the introduction of the new, 3M™ Molecular Detection Assay 2 – Cronobacter. The product joins four other next generation assays (Salmonella, E. coli O157 (counting H7), Listeria and Listeria monocytogenes) as part of the 3M™ Molecular Detection System pathogen testing platform.

Shares of Biogen Inc (NASDAQ:BIIB), jumped 0.34% and closed at $322.58 in the last trading session. The last trading range of the stock ranges between $314.61 and $324.80. The company’s Market capitalization is $70.69 Billion with the total Outstanding Shares of 217.57 million. During the 52-week trading session the minimum price at which share price traded, registered at $223.02 and reached to max level of $333.65. The EPS of company is strolling at 17.69. Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn’s disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat plaque psoriasis. The company’s products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer’s disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS – DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson’s disease; and BIIB063 for sjogren’s syndrome. The company has a planned research partnershipwith Ionis Pharmaceuticals, Inc. It offers products mainly through its own sales force, marketing groups, and third parties worldwide.

Leave a Reply

Your email address will not be published. Required fields are marked *